Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Filtronic

    MCap

    GBP107m

    Last close

    GBP0.49

    ▲ 16.00 (48.48%)

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview – Silence Therapeutics

Executive interview – Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines in the increasingly high-profile sector of RNA therapeutics, using the body’s natural mechanism of RNA interference to inhibit the expression of disease. On the back of two recent strategic deals, on 25 March 2020 the company announced a major collaboration with AstraZeneca to develop novel drugs for cardiovascular, renal, metabolic and respiratory diseases. Here to talk through the details of the AstraZeneca deal and equity investment, strategic initiatives and forthcoming milestones for Silence Therapeutics are Dr Rob Quinn, CFO and Dr John Strafford, Head of Business Development.

Silence Therapeutics (SLN) has a portfolio of siRNA drugs in early-stage testing. SLN124 for iron overload is the most advanced and is entering the clinic in Q120. SLN360 is being developed for cardiovascular disease and an IND is planned for H220.

< Previous
Next >

You may also be interested in these:

TMT

Checkit – executive interview

Investment Companies

International Public Partnerships - executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free